J Breast Cancer.  2013 Jun;16(2):133-137. 10.4048/jbc.2013.16.2.133.

The Effect of Curcumin on Breast Cancer Cells

• Liu D
• Chen Z

• KMID: 2286391
• DOI: http://doi.org/10.4048/jbc.2013.16.2.133

Abstract

Curcumin, which is extracted from the plant Curcuma longa, has been used in the therapeutic arsenal for clinical oncology. Curcumin has chemopreventive and antitumoral activities against some aggressive and recurrent cancers. The expressions and activities of various proteins, such as inflammatory cytokines and enzymes, transcription factors, and gene-products linked with cell survivals and proliferation, can be modified by curcumin. Moreover, curcumin decreases the toxic effect of mitomycin C. Though curcumin has shown highly cytotoxic to some cancer cell lines, curcumin is insoluble and instable in water. The solubility of curcumin could be enhanced by utilizing the solubilizing properties of rubusoside. In addition, the selective delivery of synthetic analogs or nanotechnology-based formulations of curcumin to tumors may improve the chemopreventive and chemotherapeutic effects. The focus of this short review is to describe how curcumin participates in antitumor processes in breast cancer cells.

Keyword

Breast neoplasms; Curcumin; Mitomycin C; Molecular mechanisms of pharmacological action

MeSH Terms

Breast
Breast Neoplasms
Cell Line
Curcuma
Curcumin
Cytokines
Diterpenes, Kaurane
Glucosides
Imidazoles
Medical Oncology
Mitomycin
Molecular Mechanisms of Pharmacological Action
Niacin
Plants
Proteins
Solubility
Transcription Factors
Water
Curcumin
Cytokines
Diterpenes, Kaurane
Glucosides
Imidazoles
Mitomycin
Molecular Mechanisms of Pharmacological Action
Niacin
Proteins
Transcription Factors
Water

Figure

• 

  Figure 1 The chemical structure of curcumin.

• 

  Figure 2 Curcumin inhibits the expression of zeste homologue 2 (EZH2) gene, AIP-1/Alix protein, Ki-67, proiferating cell nuclear antigen (PCNA), Bcl-2, and genes related to Wnt/β-catenin signaling pathway in cancer cells, but induces the expression of maspin and Bax in cancer cells. JNK=c-Jun NH2-terminal kinase; ERK=extracellular signal-regulated kinase.

• 

  Figure 3 Curcumin inhibits the expression of recepteur d'origine nantais (RON), human epidermal growth factor 2 (HER2), Akt, mitogen-activated protein kinase (MAPK), nuclear factor-κB (NF-κB), vascular endothelial growth factor (VEGF) and the phosphorylation of Src and stat3 through PRL-3 down-regulation, but induces the expression of p27 and poly (ADP-ribose) polymerase 1 (PARP-1) in cancer cells.

• 

  Figure 4 The chemical structure of mitomycin C.

• 

  Figure 5 Mitomycin C and curcumin combination treatment inhibits the expression of glucose regulatory protein (GRP58), cyclin D1, cyclin E, cyclin A, cyclin-dependent kinase 2 (CDK2), and CDK4, but induces the expression of p21 and p27 in cancer cells.

Reference

1. Park MT, Kim MJ, Kang YH, Choi SY, Lee JH, Choi JA, et al. Phytosphingosine in combination with ionizing radiation enhances apoptotic cell death in radiation-resistant cancer cells through ROS-dependent and -independent AIF release. Blood. 2005; 105:1724–1733.

2. Kunnumakkara AB, Anand P, Aggarwal BB. Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. Cancer Lett. 2008; 269:199–225.

3. Banerjee M, Singh P, Panda D. Curcumin suppresses the dynamic instability of microtubules, activates the mitotic checkpoint and induces apoptosis in MCF-7 cells. FEBS J. 2010; 277:3437–3448.

4. Hua WF, Fu YS, Liao YJ, Xia WJ, Chen YC, Zeng YX, et al. Curcumin induces down-regulation of EZH2 expression through the MAPK pathway in MDA-MB-435 human breast cancer cells. Eur J Pharmacol. 2010; 637:16–21.

5. Ramachandran C, You W. Differential sensitivity of human mammary epithelial and breast carcinoma cell lines to curcumin. Breast Cancer Res Treat. 1999; 54:269–278.

6. Prasad CP, Rath G, Mathur S, Bhatnagar D, Ralhan R. Potent growth suppressive activity of curcumin in human breast cancer cells: Modulation of Wnt/beta-catenin signaling. Chem Biol Interact. 2009; 181:263–271.

7. Prasad CP, Rath G, Mathur S, Bhatnagar D, Ralhan R. Expression analysis of maspin in invasive ductal carcinoma of breast and modulation of its expression by curcumin in breast cancer cell lines. Chem Biol Interact. 2010; 183:455–461.

8. Yang J, Cao Y, Sun J, Zhang Y. Curcumin reduces the expression of Bcl-2 by upregulating miR-15a and miR-16 in MCF-7 cells. Med Oncol. 2010; 27:1114–1118.

9. Chiu TL, Su CC. Curcumin inhibits proliferation and migration by increasing the Bax to Bcl-2 ratio and decreasing NF-kappaBp65 expression in breast cancer MDA-MB-231 cells. Int J Mol Med. 2009; 23:469–475.

10. Yoon MJ, Kim EH, Lim JH, Kwon TK, Choi KS. Superoxide anion and proteasomal dysfunction contribute to curcumin-induced paraptosis of malignant breast cancer cells. Free Radic Biol Med. 2010; 48:713–726.

11. Kim HI, Huang H, Cheepala S, Huang S, Chung J. Curcumin inhibition of integrin (alpha6beta4)-dependent breast cancer cell motility and invasion. Cancer Prev Res (Phila). 2008; 1:385–391.

12. Liu Q, Loo WT, Sze SC, Tong Y. Curcumin inhibits cell proliferation of MDA-MB-231 and BT-483 breast cancer cells mediated by down-regulation of NFkappaB, cyclinD and MMP-1 transcription. Phytomedicine. 2009; 16:916–922.

13. Zong H, Wang F, Fan QX, Wang LX. Curcumin inhibits metastatic progression of breast cancer cell through suppression of urokinase-type plasminogen activator by NF-kappa B signaling pathways. Mol Biol Rep. 2012; 39:4803–4808.

14. Kang HJ, Lee SH, Price JE, Kim LS. Curcumin suppresses the paclitaxel-induced nuclear factor-kappaB in breast cancer cells and potentiates the growth inhibitory effect of paclitaxel in a breast cancer nude mice model. Breast J. 2009; 15:223–229.

15. Lai HW, Chien SY, Kuo SJ, Tseng LM, Lin HY, Chi CW, et al. The potential utility of curcumin in the treatment of HER-2-overexpressed breast cancer: an in vitro and in vivo comparison study with herceptin. Evid Based Complement Alternat Med. 2012; 2012:486568.

16. Sen GS, Mohanty S, Hossain DM, Bhattacharyya S, Banerjee S, Chakraborty J, et al. Curcumin enhances the efficacy of chemotherapy by tailoring p65NFκB-p300 cross-talk in favor of p53-p300 in breast cancer. J Biol Chem. 2011; 286:42232–42247.

17. Narasimhan M, Ammanamanchi S. Curcumin blocks RON tyrosine kinase-mediated invasion of breast carcinoma cells. Cancer Res. 2008; 68:5185–5192.

18. Chakraborty G, Jain S, Kale S, Raja R, Kumar S, Mishra R, et al. Curcumin suppresses breast tumor angiogenesis by abrogating osteopontin-induced VEGF expression. Mol Med Rep. 2008; 1:641–646.

19. Carroll CE, Ellersieck MR, Hyder SM. Curcumin inhibits MPA-induced secretion of VEGF from T47-D human breast cancer cells. Menopause. 2008; 15:570–574.

20. Soung YH, Chung J. Curcumin inhibition of the functional interaction between integrin α6β4 and the epidermal growth factor receptor. Mol Cancer Ther. 2011; 10:883–891.

21. Somers-Edgar TJ, Scandlyn MJ, Stuart EC, Le Nedelec MJ, Valentine SP, Rosengren RJ. The combination of epigallocatechin gallate and curcumin suppresses ER alpha-breast cancer cell growth in vitro and in vivo. Int J Cancer. 2008; 122:1966–1971.

22. Calaf GM, Echiburu-Chau C, Wen G, Balajee AS, Roy D. Effect of curcumin on irradiated and estrogen-transformed human breast cell lines. Int J Oncol. 2012; 40:436–442.

23. Huang HC, Lin CL, Lin JK. 1,2,3,4,6-penta-O-galloyl-β-D-glucose, quercetin, curcumin and lycopene induce cell-cycle arrest in MDA-MB-231 and BT474 cells through downregulation of Skp2 protein. J Agric Food Chem. 2011; 59:6765–6775.

24. Wang L, Shen Y, Song R, Sun Y, Xu J, Xu Q. An anticancer effect of curcumin mediated by down-regulating phosphatase of regenerating liver-3 expression on highly metastatic melanoma cells. Mol Pharmacol. 2009; 76:1238–1245.

25. Zhou QM, Wang XF, Liu XJ, Zhang H, Lu YY, Huang S, et al. Curcumin improves MMC-based chemotherapy by simultaneously sensitising cancer cells to MMC and reducing MMC-associated side-effects. Eur J Cancer. 2011; 47:2240–2247.

26. Siddique YH, Ara G, Beg T, Gupta J, Afzal M. Assessment of cell viability, lipid peroxidation and quantification of DNA fragmentation after the treatment of anticancerous drug mitomycin C and curcumin in cultured human blood lymphocytes. Exp Toxicol Pathol. 2010; 62:503–508.

27. Zhou QM, Zhang H, Lu YY, Wang XF, Su SB. Curcumin reduced the side effects of mitomycin C by inhibiting GRP58-mediated DNA cross-linking in MCF-7 breast cancer xenografts. Cancer Sci. 2009; 100:2040–2045.

28. Zhang F, Koh GY, Jeansonne DP, Hollingsworth J, Russo PS, Vicente G, et al. A novel solubility-enhanced curcumin formulation showing stability and maintenance of anticancer activity. J Pharm Sci. 2011; 100:2778–2789.

29. Mulik RS, Monkkonen J, Juvonen RO, Mahadik KR, Paradkar AR. Transferrin mediated solid lipid nanoparticles containing curcumin: enhanced in vitro anticancer activity by induction of apoptosis. Int J Pharm. 2010; 398:190–203.

30. Ibrahim A, El-Meligy A, Fetaih H, Dessouki A, Stoica G, Barhoumi R. Effect of curcumin and Meriva on the lung metastasis of murine mammary gland adenocarcinoma. In Vivo. 2010; 24:401–408.

31. Wichitnithad W, Nimmannit U, Callery PS, Rojsitthisak P. Effects of different carboxylic ester spacers on chemical stability, release characteristics, and anticancer activity of mono-PEGylated curcumin conjugates. J Pharm Sci. 2011; 100:5206–5218.

32. Tang H, Murphy CJ, Zhang B, Shen Y, Van Kirk EA, Murdoch WJ, et al. Curcumin polymers as anticancer conjugates. Biomaterials. 2010; 31:7139–7149.